Fuse Diagnostics is a company specializing in the development of innovative, rapid, low-cost diagnostic tests that bridge the gap between laboratory-based and point-of-need testing.

Fuse Diagnostics

Fuse develops and manufactures innovative diagnostic products for a range of industries delivering lab quality information wherever it is needed through ultra-rapid, low-cost tests.

The immunoassay and PCR technologies that dominate the diagnostics industry have consistently failed to deliver lab-quality tests that are suitable for widespread decentralised use.  Using an all-new multianalytic chemistry and breakthrough product innovations Fuse has overcome the cost and performance challenges of established approaches to make accurate, point-of-need testing a reality for all.

Following hot on the heels of our £1.6m seed round we are pleased to further announce a $1m Carb-X backed programme using our technology platforms to develop a CT/NG test to help in the fight against antimicrobial resistance. 💥 🎉 

https://fuse-dx.com/news

CARB-X will award US$1 million to Fuse Diagnostics to demonstrate proof-of-concept and feasibility ahead of the development of a rapid, instrument-free diagnostic for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). 
 
Gonorrhea, caused by Neisseria gonorrhoeae, is the second-most reported bacterial sexually transmitted infection, infecting approximately 82 million people globally in 2020. Patients with gonorrhea may experience serious health effects, including pelvic inflammatory disease, chronic pain, and infertility. Untreated gonorrhea can spread to the blood stream, which can be life threatening, and increase the risk of HIV infection. 
 
The award will fund the demonstration of performance of Fuse's CT/NG test, Apex, on clinical samples. Apex CT/NG utilizes innovative device designs and molecular technologies with the potential to deliver accuracy that is equivalent to lab-based PCR systems in an ultra-rapid, low-cost format ideally suited to flexible global deployment, including areas with remote access to secondary healthcare in low- and middle-income countries (LMICs). 
 
🔗 Read more: bit.ly/3VmwmXp 

#AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #Innovation #Biotechnology #LMICs #antibiotics 

Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Government of Canada Novo Nordisk Foundation Centre for Cellular and Molecular Platforms (C-CAMP) FIND German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE)

Metric
Company Name	Fuse Diagnostics
Symbol
MSH ID	COM:FUSE-DX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare & Health Services
Country	GB
Stage
Employee Count	8
Website	fuse-dx.com
LinkedIn	fuse-diagnostics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:FUSE-DX

Fuse Diagnostics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue